Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report: By Gestation Period (0-12 Weeks, 13-24 Weeks, and 25-36 Weeks), Component, Method, Application, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Market Forecast, 2025–2034
- Published Date:Nov-2024
- Pages: 120
- Format: PDF
- Report ID: PM1836
- Base Year: 2024
- Historical Data: 2020-2023
Non-Invasive Prenatal Testing Market Overview
The Non-Invasive Prenatal Testing Market size was valued at USD 4.48 billion in 2024. The market is projected to grow from USD 4.91 billion in 2025 to USD 11.39 billion by 2034, exhibiting a CAGR of 9.8% from 2025 to 2034.
Non-invasive prenatal testing (NIPT) refers to the medical diagnostic tests that are designed to assess the risk of genetic disorders in a fetus without the need for invasive procedures.
The NIPT market is growing substantially, mainly due to the increasing prevalence of prenatal genetic disorders and rising consumer demand for early, accurate assessments of fetal health. The growing incidence of Edward's syndrome, Down syndrome, and other chromosomal abnormalities has intensified the need for effective non-invasive testing. NIPT provides a safer option than traditional methods, such as amniocentesis, delivering accurate results with a reduced risk of miscarriage.
For instance, in February 2023, according to data published by the World Health Organization (WHO), approximately 240,000 newborns worldwide die due to congenital disorders within 28 days of birth annually. Additionally, congenital disorders contribute to a further 170,000 deaths of children between the ages of 1 month and five years. This highlights the need for better prenatal screening methods like NIPT to detect these disorders early and improve outcomes for newborns and their families.
 Market.png)
To Understand More About this Research: Request a Free Sample Report
There has been a notable increase in the patient preference for NIPT, fueling significant growth in the market. This shift is primarily due to NIPT's safer profile and reduced discomfort compared to traditional invasive methods. Moreover, NIPT is recognized for its high accuracy in detecting chromosomal abnormalities with an extremely low rate of false positives and negatives. This high level of accuracy, integrated with its non-invasive nature, instills confidence in its reliability, making it the best choice among pregnant mothers seeking dependable prenatal screening. As a result, the demand for NIPT has surged.
The increasing focus on patient security and comfort continues to drive growth in the NIPT market. The fact that over 95% of patients reported high levels of satisfaction with NIPT, according to a study in Prenatal Diagnosis, is a clear testament to its appeal and effectiveness. This reflects a broader trend towards more patient-friendly and adequate prenatal care solutions.
Non-Invasive Prenatal Testing Market Trends and Drivers Analysis
Rising Technological Advancements in Sequencing Technologies and Bioinformatics
The Non-Invasive Prenatal Testing Market is rapidly developing due to continuous technological advancements in sequencing technologies and bioinformatics. Innovations in sequencing technologies, such as next-generation sequencing (NGS), have greatly enhanced the accuracy and efficiency of NIPT by enabling comprehensive analysis of fetal DNA fragments in maternal blood. Innovations such as improved cell-free DNA (cfDNA) analysis have enhanced the accuracy and reliability of NIPT.
Advancements in bioinformatics are enhancing the interpretation of complex genetic data, resulting in more reliable and personalized risk assessments. These technological developments are driving growth in the NIPT market, making it increasingly accessible and effective for healthcare providers. For instance, in May 2021, Illumina, Inc. and Next Generation Genomic Co., Ltd. announced the launch of VeriSeq NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). Illumina’s VeriSeq NIPT Solution v2 provides a more comprehensive view of the fetal genome compared to other CE-IVD NIPT products, helping healthcare providers offer better, personalized pregnancy management options for expectant parents. Such innovations drive the growth of the NIPT market.
Rise in Maternal Age
The rise in maternal age is a significant driver for the non-invasive prenatal testing (NIPT) market. As women are increasingly choosing to have children later in life, the risk of chromosomal abnormalities is also increasing. Maternal age, particularly pregnancies in women aged 35 and older, is a well-established risk factor for such conditions. This amplifies the demand for advanced prenatal screening methods like NIPT, which offers a safe, accurate, and early detection of genetic disorders. Additionally, the growing number of older expectant mothers fuels the expansion of the NIPT market, as it addresses the need for effective prenatal diagnostic solutions.
For instance, the birth rate among women aged 35–39 has surged by 272% over the past 40 years, reaching 54.2 births per 1,000 women in 2021. Similarly, the rate for women aged 40–44 has increased by 318%, reaching 12.1 births per 1,000 women in 2021. This growing trend significantly impacts individuals and healthcare systems. It increases the need for advanced prenatal screening methods like NIPT, which can manage the associated risks and improve pregnancy outcomes, further driving the expansion of the NIPT market.
 Market info.png)
Non-Invasive Prenatal Testing Market Segment Analysis
Non-Invasive Prenatal Testing Market Assessment by Method
The NIPT market segmentation, based on method, includes cell-free DNA in maternal plasma tests, biochemical screening tests, ultrasound detection, and others. In 2024, the cell-free DNA in maternal plasma tests dominated the market due to its superior accuracy and minimal risk compared to traditional invasive methods. This segment leverages advanced next-generation sequencing (NGS) technologies, enabling early and precise detection.
Additionally, technological advancements in sequencing and bioinformatics have significantly enhanced the sensitivity and specificity of cfDNA tests, making them more reliable and widely accepted. The combination of high accuracy, safety, and reduced procedural risks has propelled cfDNA.
For instance, in May 2024, Natera, Inc. announced the launch of a cfDNA-based fetal RhD test. The test assists healthcare professionals in managing patient care amid widespread shortages of Rho(D) immune globulin therapy (RhIg).
Non-Invasive Prenatal Testing Market Evaluation by Application
The NIPT market segmentation, based on application, includes monosomy, trisomy, microdeletion syndrome, and others. The trisomy segment dominated the market in 2024 owing to NIPT role in detecting common chromosomal abnormalities such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). These conditions are prevalent and have significant implications for prenatal care, making early and accurate detection crucial for expectant parents.
The rise in demand for NIPT is driven by the test's ability to provide high sensitivity and specificity in identifying these trisomies with minimal risk compared to invasive methods. As awareness of these conditions and the benefits of early diagnosis increase, more healthcare providers and parents are opting for NIPT, thereby accelerating the expansion of the trisomy segment within the market.
 Market seg.png)
Non-Invasive Prenatal Testing Market Share by Region
By region, the study provides market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the North America Non-Invasive Prenatal Testing Market dominated the global market due to the presence of advanced healthcare infrastructure, high awareness levels, and robust adoption of advanced technologies. The United States and Canada have well-established healthcare systems that are equipped with the latest diagnostic tools and technologies, facilitating the widespread availability and use of NIPT. Furthermore, strong regulatory frameworks and healthcare policies support the use of NIPT, fostering an environment conducive to market growth.
 Market reg.png)
Asia Pacific Non-Invasive Prenatal Testing Market is expected to register the fastest CAGR from 2025 to 2034. Economic growth plays a crucial role in driving this expansion, with rising disposable incomes and enhanced healthcare spending contributing to higher adoption rates. In China and India, economic development and a growing middle class are driving the demand for advanced medical technologies, including NIPT. The Asia Pacific Non-Invasive Prenatal Testing Market is driven by intense competition with strategies including price competitiveness, technological innovation, geographic expansion, and strategic partnerships. These factors foster market growth, innovation, and improved access for expectant parents. Additionally, supportive regulatory environments in China and India help to streamline the adoption of NIPT technologies. These combined factors are creating a dynamic market landscape, making Asia Pacific the fastest-growing region in the non-invasive prenatal testing market.
Non-Invasive Prenatal Testing Market – Key Players & Competitive Analysis Report
The Non-Invasive Prenatal Testing Market is highly competitive, with major players continuously innovating to enhance test accuracy and effectiveness. Companies invest in research and development while new entrants introduce innovative solutions to target specific regions, driving market dynamics. To capture market share, firms employ aggressive marketing tactics, such as social media outreach and promotional pricing.
Manufacturers in the Non-Invasive Prenatal Testing Market are focusing on optimizing production processes to reduce operational costs, enhance client value, and capture a larger market share. The Non-Invasive Prenatal Testing Market has experienced notable technological progress in recent years. Major players in the market include Agilent Technologies, Inc.; Centogene N.V.; Eurofins LifeCodexx GmbH, F; Hoffmann-La Roche Ltd.; Illumina, Inc.; Laboratory Corp. of America Holdings; MedGenome Labs Ltd.; Myriad Women’s Health, Inc.; Natera, Inc.; Progenity, Inc.; Qiagen; Quest Diagnostics, Inc.; and Thermo Fisher Scientific, Inc.
Illumina, Inc., headquartered in San Diego, California, and incorporated on April 1, 1998, is a prominent American biotechnology company specializing in advanced genetic analysis systems. In the non-invasive prenatal testing (NIPT) market, Illumina stands out for its advanced next-generation sequencing technologies, which are crucial for analyzing cell-free fetal DNA from a pregnant woman's blood. The company's VeriSeq NIPT Solution, along with its TruSeq Library Prep Kits, enhances the accuracy and efficiency of prenatal genetic screening by enabling precise detection of genetic conditions like Down syndrome. Illumina's ongoing investment in research and development further cements its position as a leading provider in this field, offering solutions that improve the safety and reliability of prenatal testing while minimizing the need for invasive procedures.
Natera, Inc., a leading player in the biotechnology sector, is renowned for its innovative contributions to the non-invasive prenatal testing (NIPT) market. Headquartered in San Carlos, California, Natera specializes in genetic testing and diagnostics, leveraging its proprietary technologies to offer comprehensive prenatal screening solutions. The company's flagship product, Panorama, is a highly advanced NIPT solution that analyzes cell-free fetal DNA to accurately assess the risk of genetic disorders such as Down syndrome, trisomy 18, and trisomy 13. Panorama's accuracy, combined with its ability to test for a broad range of conditions, positions Natera as a key leader in the prenatal testing space. Natera’s commitment to research and development, along with its focus on delivering reliable and accessible testing options, continues to drive advancements in non-invasive prenatal care and enhance patient outcomes globally.
List of Key Companies in Non-Invasive Prenatal Testing (NIPT) Market
- Agilent Technologies, Inc.
- Centogene N.V.
- Eurofins LifeCodexx GmbH
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Laboratory Corp. of America Holdings
- MedGenome Labs Ltd.
- Myriad Women’s Health, Inc.
- Natera, Inc.
- Progenity, Inc.
- Qiagen
- Quest Diagnostics, Inc.
- Thermo Fisher Scientific, Inc.
Non-Invasive Prenatal Testing Market Developments
September 2023: Yourgene Health announced the launch of MagBench Automated DNA kits and extraction for NIPT workflow. This integrated solution has enabled clinical laboratories to offer accurate and competitive non-invasive prenatal testing (NIPT) services, ensuring streamlined processes from sample collection to result generation.
September 2022: Eurofins Genoma, announced the launch of niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. The goal of niPGT-A is to offer IVF facilities a precise substitute for conventional testing while also fulfilling the many diagnostic requirements related to reproductive genetics.
August 202: Natera, Inc. declared that, as part of the Q-Sub procedure, the company has filed a pre-submission to the FDA for its non-invasive prenatal test (NIPT), called Panorama.
May 2021: Illumina, Inc. and Next Generation Genomic Co., Ltd. partnered to announce the launch of VeriSeq NIPT Solution v2 in Thailand. It is a next-generation sequencing (NGS)-based approach for noninvasive prenatal testing (NIPT).
Non-Invasive Prenatal Testing Market Segmentation
By Gestation Period Outlook (Revenue – USD Billion, 2020–2034)
- 0-12 weeks
- 13-24 weeks
- 25-36 weeks
By Component Outlook (Revenue – USD Billion, 2020–2034)
- Consumables
- Instruments
- Software
- Services
By Method Outlook (Revenue – USD Billion, 2020–2034)
- Cell-Free DNA in Maternal Plasma Tests
- Ultrasound Detection
- Biochemical Screening Tests
- Others
By Application Outlook (Revenue – USD Billion, 2020–2034)
- Monosomy
- Trisomy
- Microdeletion Syndrome
- Others
By End Use Outlook (Revenue – USD Billion, 2020–2034)
- Diagnostic Centers
- Hospitals and Clinics
- Others
By Regional Outlook (Revenue – USD Billion, 2020–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Non-Invasive Prenatal Testing (NIPT) Report Scope
|
Report Attributes |
Details |
|
Market Size Value in 2024 |
USD 4.48 Billion |
|
Market Size Value in 2025 |
USD 4.91 Billion |
|
Revenue Forecast in 2034 |
USD 11.39 Billion |
|
CAGR |
9.8% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The Non-Invasive Prenatal Testing Market size was valued at USD 4.48 billion in 2024 and is projected to be valued at USD 11.39 billion in 2034.
The market is projected to grow at a CAGR of 9.8% from 2025 to 2034.
North America held the largest share of the market in 2024 due to advanced healthcare infrastructure and high awareness levels.
The key players in the market are Agilent Technologies, Inc.; Centogene N.V.; Eurofins LifeCodexx GmbH; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; Laboratory Corp. of America Holdings; MedGenome Labs Ltd.; Myriad Women’s Health, Inc.; Natera, Inc.; Progenity, Inc.; Qiagen; Quest Diagnostics, Inc.; and Thermo Fisher Scientific, Inc.
The cell-free DNA in maternal plasma tests category dominated the market in 2024.
The trisomy segment is expected to witness the fastest CAGR in the global market.
© 2024 Polaris Market Research and Consulting. All rights reserved
